EMBLA Stock Overview
Provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Embla Medical hf. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | DKK 36.60 |
52 Week High | DKK 36.80 |
52 Week Low | DKK 26.00 |
Beta | 0.63 |
11 Month Change | 4.87% |
3 Month Change | 22.41% |
1 Year Change | 34.07% |
33 Year Change | -11.91% |
5 Year Change | -29.07% |
Change since IPO | 565.45% |
Recent News & Updates
Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts
Oct 25Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)
Oct 17Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?
Oct 02Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion
Aug 22Recent updates
Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts
Oct 25Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)
Oct 17Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?
Oct 02Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion
Aug 22Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jul 26Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)
Jul 17Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings
May 14Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 26A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)
Apr 10Is Össur hf (CPH:OSSR) Using Too Much Debt?
Mar 23Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E
Jan 21Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)
Jan 03Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly
Nov 28Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)
Nov 08A Look At The Fair Value Of Össur hf. (CPH:OSSR)
Sep 23We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt
Aug 21Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital
Jul 18Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 14Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly
May 19Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively
Mar 14A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)
Jan 21These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well
Dec 22There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital
Dec 07Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?
Sep 21Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)
Sep 02Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly
Aug 16Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price
Jun 16Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends
Jun 01Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?
May 08Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around
Feb 22Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report
Feb 03Calculating The Fair Value Of Össur hf. (CPH:OSSR)
Nov 25Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)
Oct 17Is Össur hf (CPH:OSSR) A Risky Investment?
Sep 28Calculating The Fair Value Of Össur hf. (CPH:OSSR)
Aug 21Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively
Jul 11Here's Why Össur hf (CPH:OSSR) Can Manage Its Debt Responsibly
May 28Calculating The Fair Value Of Össur hf. (CPH:OSSR)
May 07There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital
Mar 25We Think The Compensation For Össur hf.'s (CPH:OSSR) CEO Looks About Right
Mar 02We Think Össur hf (CPH:OSSR) Can Stay On Top Of Its Debt
Feb 22Does The Market Have A Low Tolerance For Össur hf.'s (CPH:OSSR) Mixed Fundamentals?
Feb 09Shareholder Returns
EMBLA | DK Medical Equipment | DK Market | |
---|---|---|---|
7D | 3.7% | -0.3% | -1.0% |
1Y | 34.1% | 10.9% | 7.5% |
Return vs Industry: EMBLA exceeded the Danish Medical Equipment industry which returned 10.9% over the past year.
Return vs Market: EMBLA exceeded the Danish Market which returned 7.5% over the past year.
Price Volatility
EMBLA volatility | |
---|---|
EMBLA Average Weekly Movement | 3.1% |
Medical Equipment Industry Average Movement | 3.6% |
Market Average Movement | 4.2% |
10% most volatile stocks in DK Market | 10.5% |
10% least volatile stocks in DK Market | 2.5% |
Stable Share Price: EMBLA has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: EMBLA's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1971 | 4,000 | Sveinn Solvason | www.emblamedical.com |
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics, Bracing & Supports, and Patient Care. The Prosthetics segment offers mechanical products, such as lower limb prosthetics and finger prostheses; and bionic products microprocessor-controlled feet, knees, hands, liners, fingers, and other components integrated.
Embla Medical hf. Fundamentals Summary
EMBLA fundamental statistics | |
---|---|
Market cap | DKK 15.33b |
Earnings (TTM) | DKK 489.67m |
Revenue (TTM) | DKK 5.96b |
31.9x
P/E Ratio2.6x
P/S RatioIs EMBLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EMBLA income statement (TTM) | |
---|---|
Revenue | US$840.31m |
Cost of Revenue | US$319.17m |
Gross Profit | US$521.13m |
Other Expenses | US$452.07m |
Earnings | US$69.07m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
Earnings per share (EPS) | 0.16 |
Gross Margin | 62.02% |
Net Profit Margin | 8.22% |
Debt/Equity Ratio | 50.7% |
How did EMBLA perform over the long term?
See historical performance and comparison